4596.T

Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.